Valuation: SCYNEXIS, Inc.

Market Cap 34.82M 31.23M 28.54M 26.06M 49.09M 3.27B 50.64M 344M 137M 1.75B 131M 128M 5.51B P/E 2026 *
-1.12x
P/E 2027 * -1.53x
Enterprise Value 34.82M 31.23M 28.54M 26.06M 49.09M 3.27B 50.64M 344M 137M 1.75B 131M 128M 5.51B EV / Sales 2026 *
73.7x
EV / Sales 2027 * 26.7x
Free-Float
97.95%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day+6.06%
1 week-7.16%
Current month-7.16%
1 month-26.78%
3 months-33.21%
6 months-54.30%
Current year-30.82%
1 week 3.28
Extreme 3.2801
4
1 month 3.28
Extreme 3.2801
4.23
Current year 3.28
Extreme 3.2801
9.12
1 year 3.28
Extreme 3.2801
9.12
3 years 3.28
Extreme 3.2801
24.56
5 years 3.28
Extreme 3.2801
64.8
10 years 3.28
Extreme 3.2801
323.2
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2023
Director of Finance/CFO 50 09/09/2026
Chief Tech/Sci/R&D Officer - 14/09/2026
Director TitleAgeSince
Director/Board Member 73 01/12/2008
Chairman 67 04/06/2015
Director/Board Member 61 01/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
18/9/26 Free

Director

11,500 0.1156%
9/9/26 Free

Chief Financial Officer

100,000 1.0051%
1/4/26 Buy

Chief Executive Officer

217,390 0.2736%
Change 5-day change 1-year change 3-year change Capi.($)
+6.06%-7.16%-26.47%-76.48% 34.82M
-0.79%-4.48%+46.48%+125.69% 1,206B
+1.43%+1.11%+48.05%+83.05% 665B
+1.07%-1.21%+32.92%+104.92% 515B
-0.36%-3.25%+45.42%+65.10% 381B
-0.14%-1.87%+70.06%+41.09% 362B
-0.78%-0.52%+30.47%+58.09% 307B
-0.80%-0.21%+7.98%+36.17% 289B
+0.03%-1.20%+43.79%+69.83% 249B
-0.41%-2.22%+40.43%+107.03% 207B
Average +0.53%-2.10%+33.91%+61.45% 417.98B
Weighted average by Cap. -0.04%-1.96%+42.71%+88.11%

Financials

2026 *2027 *
Net sales 472K 424K 387K 354K 666K 44.42M 687K 4.67M 1.86M 23.7M 1.77M 1.74M 74.82M 1.31M 1.17M 1.07M 977K 1.84M 123M 1.9M 12.9M 5.14M 65.48M 4.9M 4.8M 207M
Net income -32.76M -29.38M -26.85M -24.51M -46.18M -3.08B -47.64M -324M -129M -1.64B -123M -120M -5.19B -32.16M -28.84M -26.36M -24.06M -45.34M -3.02B -46.76M -318M -127M -1.61B -121M -118M -5.09B
Net Debt - -
Projected Income Statement - Annual - SCYNEXIS, Inc.
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
06/11/26 US$3.500 +6.06% 24,714
05/11/26 US$3.300 -14.06% 133,702
04/11/26 US$3.840 -2.54% 22,421
03/11/26 US$3.940 +3.41% 51,981
02/11/26 US$3.810 +1.06% 62,935
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - SCYNEXIS, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.500USD
Average target price
36.33USD
Spread / Average Target
+938.10%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - SCYNEXIS, Inc.
  1. Stock Market
  2. Stocks
  3. SCYX Stock